Resverlogix is a late-stage clinical biotechnology company dedicated to improving and saving the lives of patients with high-risk cardiovascular disease, diabetes mellitus, and chronic kidney disease.
Resverlogix is developing an advanced epigenetic drug called apabetalone for the treatment of high-risk cardiovascular disease patients who also have type 2 diabetes mellitus and low high-density lipoprotein (HDL). The current standard of care for these patients is administration of statins, of which, the two most common are Lipitor and Crestor. Despite maximized use, statins only manage approximately 30 percent of cardiovascular events. The opportunity for apabetalone is in addressing the huge remaining unmet medical need that can be attributed to other unmanaged risk factors such as inflammation. When used in combination with current treatments, apabetalone could address the 70 percent of unmet need in this patient group, specifically the residual inflammatory risk.
What is Apabetalone?
Apabetalone (previously known as RVX-208) is a first-in-class, safe and affordable epigenetic drug for heart disease, diabetes and chronic kidney disease. Apabetalone is currently in a Phase 3 clinical trial, which is the final stage of drug testing before a drug enters the market. Most importantly, apabetalone has proven exceptionally safe for patients in previous clinical trials. Since apabetalone is a twice daily tablet, it will be an affordable and easy to administer treatment for all patients.
Due to its unique epigenetic mechanism, we are discovering more ways that apabetalone can benefit patients among a broader range of illnesses, including neurodegenerative disease, peripheral artery disease, Fabry disease and other orphan diseases.